Texas Oncology

San Antonio, Texas 78258

2 studies enrolling now · 7 studies all time

What they study most

Advanced Breast Cancer, Low Grade Ovarian Serous Adenocarcinoma, Low Grade Serous Ovarian Cancer, Metastatic Breast Cancer, Ovarian Cancer, Relapsed or Refractory Multiple Myeloma, Renal Cell Carcinoma, Small Cell Lung Cancer, Triple Negative Breast Cancer

Studies at this site

• A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer — Recruiting now
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) — Recruiting now
• A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation — Running, not enrolling
• Palbociclib in Real World Practice — Completed
• A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma — Completed
• A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer — Completed
• A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer — Stopped early